Olaparib

ApprovedCompleted

1 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

BRCA or HRR+ Mutated Ovarian Cancer Patients

Conditions

BRCA or HRR+ Mutated Ovarian Cancer Patients

Trial Timeline

Sep 28, 2015 → Dec 17, 2021

NCT ID

NCT02476968

About Olaparib

Olaparib is a approved stage product being developed by AstraZeneca for BRCA or HRR+ Mutated Ovarian Cancer Patients. The current trial status is completed. This product is registered under clinical trial identifier NCT02476968. Target conditions include BRCA or HRR+ Mutated Ovarian Cancer Patients.

What happened to similar drugs?

0 of 4 similar drugs in BRCA or HRR+ Mutated Ovarian Cancer Patients were approved

Approved (0) Terminated (0) Active (4)

🔄Fluzoparib; Apatinib + Fluzoparib + Physician's choice chemotherapyJiangsu Hengrui MedicinePhase 3

🔄OlaparibAstraZenecaPhase 3

🔄OLAPARIB + Single agent chemotherapyAstraZenecaPhase 3

🔄Olaparib + Olaparib + Placebo + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03063710	Pre-clinical	Completed	—	—	PSR Ovarian Cancer With a BRCA Mutation
NCT05501548	Phase 2	Terminated	Jun 30, 2023	Oct 14, 2024	Prostate Cancer
NCT04951492	Phase 2	Terminated	Nov 9, 2022	Oct 15, 2023	Castration-Resistant Prostate Carcinoma
NCT05482074	Phase 2	Withdrawn	Oct 4, 2022	May 1, 2027	Recurrent Metastatic Melanoma
NCT05262608	Phase 2	UNKNOWN	Dec 7, 2021	Apr 26, 2024	Prostate Cancer
NCT04884360	Phase 3	Active	May 31, 2021	Jul 27, 2027	Ovarian Cancer
NCT04515836	Phase 2	Recruiting	Feb 19, 2021	Apr 15, 2028	Mesothelioma
NCT04532645	Pre-clinical	Completed	Jan 7, 2021	Sep 27, 2024	Ovary Cancer
NCT04421963	Phase 3	Active	Aug 4, 2020	Apr 6, 2027	Ovarian Cancer
NCT04330040	Approved	Completed	May 25, 2020	Sep 30, 2022	Ovarian Cancer
NCT04236414	Phase 1	Completed	Jan 14, 2020	Feb 4, 2025	Solid Tumours
NCT03782818	Phase 1/2	Terminated	Nov 20, 2019	Oct 31, 2024	Pulmonary Arterial Hypertension
NCT03829345	Phase 2	UNKNOWN	Jul 2, 2019	Feb 14, 2022	Oesophageal Cancer
NCT03786796	Phase 2	Recruiting	Jun 3, 2019	Mar 1, 2028	Renal Cell Carcinoma
NCT03955640	Phase 1	Terminated	May 20, 2019	Aug 26, 2021	Metastatic Malignant Neoplasm in the Chest Wall
NCT03742895	Phase 2	Active	Dec 12, 2018	Jun 30, 2026	Advanced Solid Neoplasms
NCT04152941	Pre-clinical	Completed	Oct 11, 2018	Feb 11, 2020	Relapsed Ovarian Cancers Patients
NCT03570476	Phase 2	Terminated	Sep 11, 2018	Jul 3, 2019	Prostate Adenocarcinoma Without Neuroendocrine Differentiation
NCT03470805	Phase 2	Completed	Jun 21, 2018	Jul 27, 2022	Ovarian Cancer
NCT03448718	Phase 2	Completed	Apr 17, 2018	Oct 15, 2021	Metastatic Urothelial Cancer

Competing Products

11 competing products in BRCA or HRR+ Mutated Ovarian Cancer Patients

See all competitors

Product	Company	Stage	Hype Score
Fluzoparib; Apatinib + Fluzoparib + Physician's choice chemotherapy	Jiangsu Hengrui Medicine	Phase 3	36
Veliparib	AbbVie	Pre-clinical	26
Veliparib + Cisplatin + Vinorelbine	AbbVie	Pre-clinical	26
OLAPARIB	AstraZeneca	Phase 2	35
Durvalumab + Olaparib + Tremelimumab	AstraZeneca	Phase 2	35
olaparib	AstraZeneca	Pre-clinical	26
Olaparib	AstraZeneca	Phase 3	40
OLAPARIB + Single agent chemotherapy	AstraZeneca	Phase 3	40
Olaparib + Olaparib + Placebo + Placebo	AstraZeneca	Phase 3	40
Talazoparib Oral Capsule	Pfizer	Phase 1	21
INO-5401 + INO-9012	Inovio Pharmaceuticals	Phase 1	23